0 CHECKOUT

Septic Shock - Pipeline Review, H1 2015

  • ID: 3266331
  • April 2015
  • 77 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Adrenomed AG
  • Compugen Ltd.
  • Huons Co., Ltd.
  • InflaRx GmbH
  • Noxxon Pharma AG
  • Orion Oyj
  • MORE

Septic Shock - Pipeline Review, H1 2015

Summary

This, ‘Septic Shock - Pipeline Review, H1 2015’, provides an overview of the Septic Shock’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Septic Shock, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Septic Shock and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adrenomed AG
  • Compugen Ltd.
  • Huons Co., Ltd.
  • InflaRx GmbH
  • Noxxon Pharma AG
  • Orion Oyj
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Septic Shock Overview
Therapeutics Development
Pipeline Products for Septic Shock - Overview
Pipeline Products for Septic Shock - Comparative Analysis
Septic Shock - Therapeutics under Development by Companies
Septic Shock - Therapeutics under Investigation by Universities/Institutes
Septic Shock - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Septic Shock - Products under Development by Companies
Septic Shock - Products under Investigation by Universities/Institutes
Septic Shock - Companies Involved in Therapeutics Development
Adrenomed AG
Compugen Ltd.
Ferring International Center S.A.
Huons Co., Ltd.
InflaRx GmbH
Lixte Biotechnology Holdings, Inc.
Noxxon Pharma AG
Orion Oyj
Pharmazz, Inc.
Spider Biotech
Takeda Pharmaceutical Company Limited
XImmune AB
Septic Shock - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
adrecizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BTZO-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
centhaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CGEN-25068 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBN-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBN-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBN-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HU-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LB-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LB-1148 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levosimendan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MFH-147 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOXD-20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-190 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB-056 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selepressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize TLR-4 for Septicemia and Septic Shock - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-14 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Septic Shock - Recent Pipeline Updates
Septic Shock - Dormant Projects
Septic Shock - Discontinued Products
Septic Shock - Product Development Milestones
Featured News & Press Releases
Feb 02, 2015: Leading BioSciences Receives FDA IND Clearance To Proceed With A Randomized, Multi-Center Phase 2 Clinical Trial Using LB1148 To Treat Septic Shock
Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Septic Shock, H1 2015
Number of Products under Development for Septic Shock - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Septic Shock - Pipeline by Adrenomed AG, H1 2015
Septic Shock - Pipeline by Compugen Ltd., H1 2015
Septic Shock - Pipeline by Ferring International Center S.A., H1 2015
Septic Shock - Pipeline by Huons Co., Ltd., H1 2015
Septic Shock - Pipeline by InflaRx GmbH, H1 2015
Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015
Septic Shock - Pipeline by Noxxon Pharma AG, H1 2015
Septic Shock - Pipeline by Orion Oyj, H1 2015
Septic Shock - Pipeline by Pharmazz, Inc., H1 2015
Septic Shock - Pipeline by Spider Biotech, H1 2015
Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Septic Shock - Pipeline by XImmune AB, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Septic Shock Therapeutics - Recent Pipeline Updates, H1 2015
Septic Shock - Dormant Projects, H1 2015
Septic Shock - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Septic Shock, H1 2015
Number of Products under Development for Septic Shock - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Adrenomed AG
Compugen Ltd.
Ferring International Center S.A.
Huons Co., Ltd.
InflaRx GmbH
Lixte Biotechnology Holdings, Inc.
Noxxon Pharma AG
Orion Oyj
Pharmazz, Inc.
Spider Biotech
Takeda Pharmaceutical Company Limited
XImmune AB

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.